{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:33:14Z","timestamp":1787931194479,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bioorg.2019.103127","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T02:06:07Z","timestamp":1563415567000},"page":"103127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors"],"prefix":"10.1016","volume":"91","author":[{"given":"Mamdouh F.A.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa G.M.","family":"Youssif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montaser Sh. A.","family":"Shaykoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa H.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakheet E.M.","family":"Elsadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Aboraia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal El-Din A.","family":"Abuo-Rahma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2019.103127_b0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bioorg.2017.03.005","article-title":"Design, synthesis, docking studies and biological evaluation of novel chalcone derivatives as potential histone deacetylase inhibitors","volume":"72","author":"Mohamed","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bioorg.2018.06.003","article-title":"Novel pyrrol-2(3H)-ones and pyridazin-3(2H)-ones carrying quinoline scaffold as anti-proliferative tubulin polymerization inhibitors","volume":"80","author":"Abdelbaset","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0015","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2741\/1668","article-title":"New anti-cancer strategies: epigenetic therapies and biomarkers","volume":"10","author":"Balch","year":"2005","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bioorg.2019.103127_b0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bioorg.2019.103127_b0025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.bioorg.2019.103127_b0030","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.bmcl.2016.03.010","article-title":"Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay","volume":"26","author":"Son","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.103127_b0035","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/13543784.2010.510514","article-title":"The clinical development of histone deacetylase inhibitors as targeted anticancer drugs","volume":"19","author":"Marks","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2019.103127_b0040","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.bioorg.2019.103127_b0045","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2019.103127_b0050","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2019.103127_b0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrd4583","article-title":"HDAC inhibitors still need a home run, despite recent approval","volume":"14","author":"Guha","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2019.103127_b0060","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00044-012-0324-3","article-title":"Synthesis and biological evaluation of novel series of thieno[2,3-d]pyrimidine derivatives as anticancer and antimicrobial agents","volume":"22","author":"Habib","year":"2013","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2019.103127_b0065","first-page":"500","article-title":"Synthesis of new [1,3,4]thiadiazolo[3,2-a]thieno[2,3-d]pyrimidinone derivatives with antiinflammatory activity","volume":"55","author":"Modica","year":"2000","journal-title":"Pharmazie"},{"key":"10.1016\/j.bioorg.2019.103127_b0070","first-page":"301","article-title":"Synthesis and antiinflammatory activity of certain thienopyrimidine derivatives","volume":"135","author":"el-Kerdawy","year":"1996","journal-title":"Boll Chim. Farmaceutico"},{"key":"10.1016\/j.bioorg.2019.103127_b0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0223-5234(02)01442-3","article-title":"Synthesis and preliminary evaluation of some N-[5-(2-furanyl)-2-methyl-4-oxo-4H-thieno[2,3-d]pyrimidin-3-yl]-carboxamide and 3-substituted-5-(2-furanyl)-2-methyl-3H-thieno[2,3-d]pyrimidin-4-ones as antimicrobial agents","volume":"38","author":"Chambhare","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0080","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/jps.2600650507","article-title":"Synthesis of 3-substituted thieno [2, 3-d] pyrimidin-4(3H)-one-2-mercaptoacetic acids and their ethyl esters for pharmacological screening","volume":"65","author":"Devani","year":"1976","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2019.103127_b0085","first-page":"689","article-title":"Synthesis and pharmacological evaluation of thieno[2,3-d]pyrimidin-2,4-dione and 5H-pyrimido [5,4-b]indol-2,4-dione derivatives","volume":"50","author":"Santagati","year":"1995","journal-title":"Farmaco"},{"key":"10.1016\/j.bioorg.2019.103127_b0090","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1016\/j.bmcl.2005.07.072","article-title":"Parallel synthesis and biological evaluation of 5,6,7,8-tetrahydrobenzothieno[2,3-d]pyrimidin-4(3H)-one cytotoxic agents selective for p21-deficient cells","volume":"15","author":"Jennings","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.103127_b0095","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/jm00271a034","article-title":"Heterocyclic compounds. 4. Synthesis and antiinflammatory activity of some substituted thienopyrimidones","volume":"15","author":"Manhas","year":"1972","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bmcl.2003.10.030","article-title":"Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity","volume":"14","author":"Munchhof","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.103127_b0105","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1016\/j.bmcl.2005.05.127","article-title":"Inhibition of tumor cell proliferation by thieno[2,3-d]pyrimidin-4(1H)-one-based analogs","volume":"15","author":"Wang","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.103127_b0110","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ejmech.2017.07.028","article-title":"Thienopyrimidine derivatives exert their anticancer efficacy via apoptosis induction, oxidative stress and mitotic catastrophe","volume":"138","author":"Amawi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.fjps.2015.09.001","article-title":"Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents","volume":"1","author":"Elrazaz","year":"2015","journal-title":"Future J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2019.103127_b0120","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1021\/jm100607r","article-title":"Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and michael acceptor group for maximal potency","volume":"53","author":"Wu","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0125","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/156800909788166619","article-title":"Design of new drug molecules to be used in reversing multidrug resistance in cancer cells","volume":"9","author":"Mayur","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bioorg.2019.103127_b0130","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1016\/j.bmc.2009.08.068","article-title":"Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity","volume":"17","author":"Solomon","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cber.19660990116","article-title":"Heterocyclen aus CH-aciden Nitrilen, VIII. 2-Amino-thiophene aus methylenaktiven Nitrilen, Carbonylverbindungen und Schwefel","volume":"99","author":"Gewald","year":"1996","journal-title":"Chem. Ber."},{"key":"10.1016\/j.bioorg.2019.103127_b0140","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/11070498","article-title":"Synthesis of some thienopyrimidine derivatives","volume":"11","author":"El-Baih","year":"2006","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2019.103127_b0145","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/jm031036f","article-title":"3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies","volume":"47","author":"Ragno","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0150","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/jm030990+","article-title":"3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and\/or -C4 substitutions on biological activity","volume":"47","author":"Mai","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0155","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1016\/j.tetlet.2006.06.090","article-title":"Synthesis of alpha-chloroamides in water","volume":"47","author":"Harte","year":"2006","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.bioorg.2019.103127_b0160","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1016\/j.bmc.2011.08.001","article-title":"Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents","volume":"19","author":"Qiu","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0165","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1021\/acs.jmedchem.5b00621","article-title":"Introduction of peripheral carboxylates to decrease the charge on Tm(3+) DOTAM-Alkyl complexes: implications for detection sensitivity and in vivo toxicity of PARACEST MRI contrast agents","volume":"58","author":"Suchy","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0170","article-title":"An update on antitumor activity of naturally occurring chalcones","volume":"2013","author":"Zhang","year":"2013","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.bioorg.2019.103127_b0175","first-page":"2913","article-title":"Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis","volume":"62","author":"Huang","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2019.103127_b0180","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF00689967","article-title":"Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties","volume":"30","author":"Sobottka","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2019.103127_b0185","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","article-title":"Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability","volume":"288","author":"Lauffer","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejmech.2009.09.025","article-title":"Substituted 2-aminothiopen-derivatives: a potential new class of GluR6-antagonists","volume":"45","author":"Briel","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0195","article-title":"Sulforaphane epigenetically regulates innate immune responses of porcine monocyte-derived dendritic cells induced with lipopolysaccharide","volume":"10","author":"Qu","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2019.103127_b0200","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.bmc.2014.03.019","article-title":"Search for novel histone deacetylase inhibitors. Part II: design and synthesis of novel isoferulic acid derivatives","volume":"22","author":"Lu","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0205","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1016\/j.bmc.2013.09.021","article-title":"Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors","volume":"21","author":"Wang","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2017.03.064","article-title":"Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors","volume":"133","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103127_b0215","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ejmech.2018.07.024","article-title":"Synthesis, anticancer activity and molecular modeling studies of 1,2,4-triazole derivatives as EGFR inhibitors","volume":"156","author":"El-Sherief","year":"2018","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206818314433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206818314433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:51:52Z","timestamp":1758613912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206818314433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":43,"alternative-id":["S0045206818314433"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.103127","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.103127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103127"}}